Navigation Links
Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States
Date:12/2/2008

MALVERN, Pa., Dec. 2 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Ortho-McNeil-Janssen Pharmaceuticals' Levaquin is the preferred quinolone antibiotic among more than half of all general medical-surgical hospitals in the United States. Quinolone antibiotics are used to treat lung, sinus, skin and urinary tract infections caused by numerous bacterial pathogens.

"Based on our October 2008 audit, intravenous Levaquin was stocked in more hospitals than both Bayer's intravenous Cipro and generic intravenous ciprofloxacin combined," stated Matthew W. Mahr, Pharm.D., M.B.A., analyst at AMR.

The newly released edition of the Quinolone Monthly Monitor (U.S.) also finds that over 70 percent of hospitals reported having a closed hospital formulary for antibiotics. Large hospitals were found to be most likely to have a closed formulary for antibiotics. These closed formularies create restrictions on what can be prescribed in the hospital making it more difficult for a prescriber to use that medication.

Why Pharmaceutical Companies Need this Information

The Quinolone Monthly Monitor (U.S.) enables pharmaceutical companies to monitor formulary, stocking and restriction status of selected quinolone antibiotics. This study also gives information about the Pharmacy and Therapeutics Committee's actions for quinolones, which drive formulary and restriction status for these products.

About The Quinolone Monthly Monitor (U.S.)

The Quinolone Monthly Monitor (U.S.) is the industry's most comprehensive market research study of the formulary status of quinolone antibiotics. This study has been conducted monthly since June 1992 by collecting data from 300 pharmacy directors from a group of demographically representative acute care hospitals within the country.

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales             Elizabeth Marshall
    Decision Resources          Decision Resources, Inc.
    781-296-2691                781-296-2563
    nmorales@dresources.com     emarshall@dresources.com

'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. LegalView Reveals Details of the FDA Mandated Black Box Warning For Fluoroquinolone Antibiotics Such as Cipro and Levaquin
2. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
3. Preferred Care Gold Ranked Number One Medicare Advantage Health Plan Nationally In U.S. News & World Report/NCQA Americas Best Health Plans 2008 Listing
4. MVP Health Care and IncentOne Partner to Provide Member Incentives for MVP and Preferred Care WellStyle Extras Program
5. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares
6. Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox
7. Mylan Declares Quarterly Preferred Stock Dividend
8. NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
9. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
10. Part D Advisors, Inc. Signs On as a TPAA Preferred Partner
11. PD-Rx Completes Call for Preferred A Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: